Reproductive · Urology
The facts most likely to be tested
BPH involves stromal and epithelial hyperplasia occurring primarily in the transition zone of the prostate gland.
Patients typically present with lower urinary tract symptoms (LUTS), including hesitancy, weak urinary stream, post-void dribbling, and nocturia.
Digital rectal examination (DRE) classically reveals a symmetrically enlarged, smooth, and nontender prostate gland.
First-line pharmacotherapy for moderate symptoms is an alpha-1 adrenergic antagonist (e.g., tamsulosin) to provide rapid relief by relaxing smooth muscle in the bladder neck and prostate.
5-alpha-reductase inhibitors (e.g., finasteride) are indicated for patients with a large prostate volume to reduce gland size by inhibiting the conversion of testosterone to dihydrotestosterone (DHT).
Transurethral resection of the prostate (TURP) remains the gold standard surgical treatment for patients who fail medical therapy or develop complications.
Absolute indications for surgical intervention include refractory urinary retention, recurrent urinary tract infections, recurrent gross hematuria, bladder stones, or chronic kidney disease secondary to obstruction.
Vignette unlocked
A 72-year-old male presents to the clinic complaining of a weak urinary stream, hesitancy, and nocturia three times per night. He reports no dysuria, hematuria, or fever. On physical examination, a digital rectal exam reveals a symmetrically enlarged, smooth, and nontender prostate. Urinalysis is negative for infection, and his serum creatinine is within normal limits.
What is the most appropriate initial pharmacotherapy to improve this patient's symptoms?
Alpha-1 adrenergic antagonist (e.g., tamsulosin)
The patient's presentation is classic for BPH, and alpha-1 antagonists are the first-line treatment to provide rapid symptomatic relief by relaxing prostatic smooth muscle.
Full handout
High yield triage
Etiology / Epidemiology
Age-related stromal and epithelial hyperplasia in men >50. Prevalence approaches 90% by age 80.
Clinical Manifestations
Obstructive and irritative voiding symptoms. Hesitancy, nocturia, and weak urinary stream.
Diagnosis
Clinical diagnosis supported by Digital Rectal Exam (DRE) showing a smooth, firm, elastic, non-tender prostate.
Treatment
Tamsulosin (alpha-1 blocker) for rapid symptom relief; Finasteride (5-alpha reductase inhibitor) for prostate shrinkage.
Prognosis
Risk of acute urinary retention and chronic kidney disease. Monitor with AUA Symptom Score.
Full handout
Epidemiology & Etiology
BPH is an androgen-dependent process occurring in the transition zone of the prostate. It is the most common benign neoplasm in men, with incidence increasing linearly after age 40. Age and family history are the primary non-modifiable risk factors.
Pertinent Anatomy
Hyperplasia occurs specifically in the transition zone (periurethral), which explains the early onset of obstructive symptoms. The peripheral zone is typically spared, which is where most prostate cancers originate.
Pathophysiology
Dihydrotestosterone (DHT) promotes prostatic growth via androgen receptors. Increased smooth muscle tone in the prostate and bladder neck contributes to dynamic obstruction, while physical enlargement causes static obstruction. This leads to bladder hypertrophy, detrusor instability, and eventual decompensation.
Clinical Manifestations
Patients present with LUTS (Lower Urinary Tract Symptoms) including hesitancy, intermittency, post-void dribbling, and nocturia. DRE reveals a smooth, firm, elastic prostate; a hard, nodular prostate suggests malignancy. Red flags include hematuria, sudden urinary retention, or elevated creatinine indicating post-renal azotemia.
Diagnosis
Diagnosis is primarily clinical. Digital Rectal Exam is mandatory to rule out cancer. PSA (Prostate-Specific Antigen) is often elevated but is non-specific; a value >4.0 ng/mL warrants further investigation. Urinalysis is required to exclude infection or hematuria.
Treatment
Tamsulosin is the first-line alpha-1 blocker for immediate symptom relief by relaxing smooth muscle. Finasteride is indicated for patients with large prostates to reduce volume, though it takes 6-12 months for effect. Contraindications for alpha-blockers include concurrent use of PDE5 inhibitors due to severe hypotension. TURP (Transurethral Resection of the Prostate) is the surgical gold standard for refractory cases.
Prognosis
Complications include bladder stones, recurrent UTIs, and hydronephrosis. Patients should be monitored using the AUA Symptom Score to track disease progression and treatment efficacy.
Differential Diagnosis
Prostate Cancer: hard, nodular, or asymmetric prostate on DRE
Prostatitis: tender, warm, boggy prostate with fever/dysuria
Urethral Stricture: history of trauma or STI/urethritis
Neurogenic Bladder: history of diabetes or spinal cord injury
Bladder Cancer: painless gross hematuria